Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.35 |
| ▸ | FEN1 | P39748 | 6/20 | 0.35 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616214 | 0.89 | ALOX5AP (0.38) | ALOX5APFEN1ERN1F2RL3AR | |
| SCHEMBL16616334 | 0.89 | SSTR5 (0.35) | ALOX5APFEN1ERN1GRM2SSTR5 | |
| SCHEMBL16670157 | 0.89 | GRM2 (0.34) | ALOX5APFEN1GRM2MAPK14SSTR5 | |
| SCHEMBL17535933 | 0.84 | SSTR5 (0.42) | ALOX5APFEN1ERN1SSTR5 | |
| SCHEMBL16616143 | 0.81 | ALPL (0.39) | MAPK14SSTR5 | |
| SCHEMBL16616633 | 0.81 | SSTR5 (0.39) | ALOX5APFEN1AMY1AGRM2MAPK14 | |
| SCHEMBL16616618 | 0.80 | AR (0.33) | ALOX5APFEN1AR | |
| SCHEMBL16670330 | 0.80 | ALOX5AP (0.36) | ALOX5APFEN1GRM2MAPK14AR | |
| SCHEMBL17535544 | 0.77 | ERN1 (0.41) | ERN1 | |
| SCHEMBL16056281 | 0.76 | ALOX5AP (0.36) | ALOX5APFEN1ERN1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | ALOX5AP 1142/4885FEN1 4835/4885ERN1 3408/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | ALOX5AP 2601/4885FEN1 4838/4885ERN1 3034/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | ALOX5AP 1085/4885FEN1 4821/4885ERN1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.